177 related articles for article (PubMed ID: 37573690)
1. CXCL5 promotes lipotoxicity of hepatocytes through upregulating NLRP3/Caspase-1/IL-1β signaling in Kupffer cells and exacerbates nonalcoholic steatohepatitis in mice.
Qi J; Yan X; Li L; Qiu K; Huang W; Zhou Z
Int Immunopharmacol; 2023 Oct; 123():110752. PubMed ID: 37573690
[TBL] [Abstract][Full Text] [Related]
2. NLRP3 Deletion Inhibits the Non-alcoholic Steatohepatitis Development and Inflammation in Kupffer Cells Induced by Palmitic Acid.
Cai C; Zhu X; Li P; Li J; Gong J; Shen W; He K
Inflammation; 2017 Dec; 40(6):1875-1883. PubMed ID: 28730512
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of NLRP3 inflammasome by thioredoxin-interacting protein in mouse Kupffer cells as a regulatory mechanism for non-alcoholic fatty liver disease development.
He K; Zhu X; Liu Y; Miao C; Wang T; Li P; Zhao L; Chen Y; Gong J; Cai C; Li J; Li S; Ruan XZ; Gong J
Oncotarget; 2017 Jun; 8(23):37657-37672. PubMed ID: 28499273
[TBL] [Abstract][Full Text] [Related]
4. Fatty acid activates NLRP3 inflammasomes in mouse Kupffer cells through mitochondrial DNA release.
Pan J; Ou Z; Cai C; Li P; Gong J; Ruan XZ; He K
Cell Immunol; 2018 Oct; 332():111-120. PubMed ID: 30103942
[TBL] [Abstract][Full Text] [Related]
5. Cathepsin B inhibition ameliorates the non-alcoholic steatohepatitis through suppressing caspase-1 activation.
Tang Y; Cao G; Min X; Wang T; Sun S; Du X; Zhang W
J Physiol Biochem; 2018 Nov; 74(4):503-510. PubMed ID: 30019185
[TBL] [Abstract][Full Text] [Related]
6. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice.
Mridha AR; Wree A; Robertson AAB; Yeh MM; Johnson CD; Van Rooyen DM; Haczeyni F; Teoh NC; Savard C; Ioannou GN; Masters SL; Schroder K; Cooper MA; Feldstein AE; Farrell GC
J Hepatol; 2017 May; 66(5):1037-1046. PubMed ID: 28167322
[TBL] [Abstract][Full Text] [Related]
7. Cardiolipin inhibitor ameliorates the non-alcoholic steatohepatitis through suppressing NLRP3 inflammasome activation.
Liu J; Wang T; He K; Xu M; Gong JP
Eur Rev Med Pharmacol Sci; 2019 Sep; 23(18):8158-8167. PubMed ID: 31599445
[TBL] [Abstract][Full Text] [Related]
8. The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells.
Yang SH; Wu H; Yi ZJ; Lai X
Eur Rev Med Pharmacol Sci; 2021 Jun; 25(11):4017-4026. PubMed ID: 34156680
[TBL] [Abstract][Full Text] [Related]
9. Exercise suppresses NLRP3 inflammasome activation in mice with diet-induced NASH: a plausible role of adropin.
Yang W; Liu L; Wei Y; Fang C; Liu S; Zhou F; Li Y; Zhao G; Guo Z; Luo Y; Li L
Lab Invest; 2021 Mar; 101(3):369-380. PubMed ID: 33268842
[TBL] [Abstract][Full Text] [Related]
10. A new mechanism of obeticholic acid on NASH treatment by inhibiting NLRP3 inflammasome activation in macrophage.
Huang S; Wu Y; Zhao Z; Wu B; Sun K; Wang H; Qin L; Bai F; Leng Y; Tang W
Metabolism; 2021 Jul; 120():154797. PubMed ID: 33984334
[TBL] [Abstract][Full Text] [Related]
11. Hepatocyte pyroptosis and release of inflammasome particles induce stellate cell activation and liver fibrosis.
Gaul S; Leszczynska A; Alegre F; Kaufmann B; Johnson CD; Adams LA; Wree A; Damm G; Seehofer D; Calvente CJ; Povero D; Kisseleva T; Eguchi A; McGeough MD; Hoffman HM; Pelegrin P; Laufs U; Feldstein AE
J Hepatol; 2021 Jan; 74(1):156-167. PubMed ID: 32763266
[TBL] [Abstract][Full Text] [Related]
12. Impaired mitophagy triggers NLRP3 inflammasome activation during the progression from nonalcoholic fatty liver to nonalcoholic steatohepatitis.
Zhang NP; Liu XJ; Xie L; Shen XZ; Wu J
Lab Invest; 2019 Jun; 99(6):749-763. PubMed ID: 30700851
[TBL] [Abstract][Full Text] [Related]
13. Fatty acid and endotoxin activate inflammasomes in mouse hepatocytes that release danger signals to stimulate immune cells.
Csak T; Ganz M; Pespisa J; Kodys K; Dolganiuc A; Szabo G
Hepatology; 2011 Jul; 54(1):133-44. PubMed ID: 21488066
[TBL] [Abstract][Full Text] [Related]
14. Dietary saturated fatty acid and polyunsaturated fatty acid oppositely affect hepatic NOD-like receptor protein 3 inflammasome through regulating nuclear factor-kappa B activation.
Sui YH; Luo WJ; Xu QY; Hua J
World J Gastroenterol; 2016 Feb; 22(8):2533-44. PubMed ID: 26937141
[TBL] [Abstract][Full Text] [Related]
15. Toll-like receptor 2 and palmitic acid cooperatively contribute to the development of nonalcoholic steatohepatitis through inflammasome activation in mice.
Miura K; Yang L; van Rooijen N; Brenner DA; Ohnishi H; Seki E
Hepatology; 2013 Feb; 57(2):577-89. PubMed ID: 22987396
[TBL] [Abstract][Full Text] [Related]
16. Benzyl isothiocyanate ameliorates high-fat/cholesterol/cholic acid diet-induced nonalcoholic steatohepatitis through inhibiting cholesterol crystal-activated NLRP3 inflammasome in Kupffer cells.
Chen HW; Yen CC; Kuo LL; Lo CW; Huang CS; Chen CC; Lii CK
Toxicol Appl Pharmacol; 2020 Apr; 393():114941. PubMed ID: 32126212
[TBL] [Abstract][Full Text] [Related]
17. Sweroside Prevents Non-Alcoholic Steatohepatitis by Suppressing Activation of the NLRP3 Inflammasome.
Yang G; Jang JH; Kim SW; Han SH; Ma KH; Jang JK; Kang HC; Cho YY; Lee HS; Lee JY
Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32316419
[TBL] [Abstract][Full Text] [Related]
18. CXCL5 Promotes Acetaminophen-Induced Hepatotoxicity by Activating Kupffer Cells.
Qiu K; Pan Y; Huang W; Li M; Yan X; Zhou Z; Qi J
Int J Mol Sci; 2023 Jul; 24(15):. PubMed ID: 37569554
[TBL] [Abstract][Full Text] [Related]
19. Stimulation of soluble guanylate cyclase exerts antiinflammatory actions in the liver through a VASP/NF-κB/NLRP3 inflammasome circuit.
Flores-Costa R; Duran-Güell M; Casulleras M; López-Vicario C; Alcaraz-Quiles J; Diaz A; Lozano JJ; Titos E; Hall K; Sarno R; Masferrer JL; Clària J
Proc Natl Acad Sci U S A; 2020 Nov; 117(45):28263-28274. PubMed ID: 33106416
[TBL] [Abstract][Full Text] [Related]
20. Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis.
Povero D; Lazic M; McBride C; Ambrus-Aikelin G; Stansfield R; Johnson CD; Santini AM; Pranadinata RF; McGeough MD; Stafford JA; Hoffman HM; Feldstein AE; Veal JM; Bain G
J Pharmacol Exp Ther; 2023 Aug; 386(2):242-258. PubMed ID: 37308266
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]